PET for Dementia Trials

PET for Dementia Trials

Additionally, in a National Coverage Determination for PET (FDG) for Dementia and Neurodegenerative Diseases (220.6.13) the Centers for Medicare & Medicaid Services (CMS) indicated that an FDG-PET scan is considered reasonable and necessary in patients with mild cognitive impairment or early dementia only in the context of an approved clinical trial that contains patient safeguards and protections to ensure proper administration, use and evaluation of the FDG-PET scan.

Facility Name Provider Number Date Approved State
95 1644600
2009-10-09
California
460009
2009-02-17
Utah
1073605879
2009-02-17
South Carolina
W11817A
2007-01-12
California
UCLA Medical Center
HW13029
2006-06-07
California
University of Buffalo
14414A
2007-03-12
New York
Page Last Modified:
09/06/2023 04:57 PM